About Us
------------------------------
Our Philosophy
------------------------------
Mission Statement
------------------------------

What is BT
------------------------------
How BT Works
------------------------------
Why BT Works

------------------------------
Will it Work for You
------------------------------
History of BT
------------------------------
Diseases Treated
------------------------------
Physical Science
------------------------------
Bibliography
------------------------------
Testimonials
------------------------------
Cancer Glossary
------------------------------
Links & Literature
------------------------------
Newsletter
------------------------------
Physicians
------------------------------
Contact Us
 
 

 
 

 
 
 
 

History of BT


 
Considerable research into the use of UV light for treatment of disease was initiated in the 1870’s.

One of the first researchers to experiment with UV light was Niels Ryberg Finsen, who won the Nobel Prize for “Physiology of Medicine” in 1903 for the treatment of 300 people suffering from Lupus in Denmark.

 
NIELS FINSEN - FATHER OF PHOTOTHERAPY:

• Won Nobel Prize in Physiology & Medicine in 1903

• “In recognition of his contribution to the treatment of diseases, especially Lupus Vulgaris, with concentrated light radiation, whereby he has opened a new avenue for medical science“

• Dr. Finsen’s contribution to medicine is un-parallel. He treated 300 patients with Lupus Vulgaris and demonstrated 100% success rates.

• Even today, we have nothing in our arsenal of medications that can produce such results.

 
• Imagine the cure to an Auto-Immune Disease 100 years ago and no one noticed.
 

In 1922 another pioneer to experiment with Light Therapy was Kurt Naswitis who directly irradiated the blood with UV light through a shunt.

During the 1920’s and continuing through the 1930’s the infamous Seattle scientist Dr. Emmett Knott, Dr. Sc., sought to harness, in an extracorporeal way, the known bactericidal property of ultraviolet rays in order to treat infectious diseases of the blood. On September 11, 1928 Knott received Patent Number 1,683,877 for the “Means for Treating Bloodstream Infections” as a result of a application filed on March 3, 1927 for a UV apparatus he built. Subsequently he received Patent Number 2,308,516 on January 19, 1943.


LESTER EDBLOM AND EMMET KNOTT

• Lester Edblom, medical student and Dr. Emmet Knott scientist, developed the first Hemo-Irradiator, vacuum extraction system and cuvette.

• The first Patent was issued in the USA for a UV-Irradiator. September 11, 1928.

• Thousands of people were treated between the 1930’s up to 1959 with a 98% success rate

Patent. Figs: 1, 2, 3, 4 and 5 detail the, extraction and dilution process, the Cuvette, Irradiation Chamber, some Tubing and an Adaptor.


Knott Hemo-Irradiator (Circa 1947)

Original Model used extensively until the late 1950’s. that contained certain changes to the apparatus. The machine received an FDA “grandfather” status as a device that was sold and distributed in interstate commerce prior to 1976.

By the early 1940’s UV blood irradiation was being used in several American hospitals. Into the middle of the 1940’s, numerous reports were made about the efficacy for infections and complete safety of UV blood irradiation therapy. With the emergence of antibiotic therapy, and the billions being pushed on the medical industry to the Doctors by the pharmaceutical companies, UBI therapy was suddenly pushed aside for a more profitable form of treatment.

A multitude of articles appeared in the American literature detailing a novel treatment for various infections and diseases. This treatment had a cure rate of 98% to 100% in early and moderately advanced infections, and approximately 50% in terminally moribund patients. Healing was not limited to just bacterial infections, but was also viral, ( acute polio ), Lupus, wounds, asthma, and arthritis.

The “Tulsa World Newspaper” in 1951 describes how Biophotonic Therapy helped in the fight against Nephritis in children. This particular study demonstrated a success rate of 97%.

In the ensuing years, Germany literature demonstrated the effectiveness of UV irradiation in vascular conditions. Additionally, more thorough observations of significant improvement in many physiologic processes and parameters have been reported. German literature has also demonstrated profound improvements in a number of biochemical and hematological markers.

By the late 1940’s several dozen physicians were regularly using Knott’s device according to the technique established by Knott. They treated bacterial infections, pneumonia, poliomyelitis, botulism, non-healing wounds, encephalitis, peritonitis, asthma, pelvic inflammatory disease (PID), Biliary Disease, Hepatitis, and many other infectious, inflammatory, and Auto-Immune disorders.

Surgeons were particularly interested in the use of UBI pre- and post-operationally to treat infections. And The American Journal of Surgery ran many articles on Biophotonic Therapy Pre and Post Operation.

Proponents of UBI published their findings in dozens of scientific articles. Thousands of patients were treated at leading centers like Georgetown University Hospital. UBI fared well in several clinical trials with controls.

Caption from preceding Slide Reads:
“NEW YORK INFIRMARY USES NEW ALLY IN RESEARCH AGAINST RHEUMATIC FEVER"


Research workers find evidence that the Heart recovers more rapidly from the ravaging effects of Rheumatic Fever when the blood of the patient is irradiated with Ultraviolet Light. To date, ninety-eight (98) Children have already been returned to good health by this simple treatment.”

Article proving Biophotonic Therapy was utilized extensively in the U.S. in the 1940’s. This article describes the beneficial effects of Biophotonic Therapy in 98 children with Rheumatic Fever.


In Europe, Czech physician Karel Havlicek and others began using UBI via muscular reinjection of small doses, often just 10 ml. Federico Wehrli treated oxygenated blood with UV in a procedure termed Hematogenic Oxidation Therapy ( HOT ). Since then, HOT has enjoyed certain popularity in Central Europe.

The dramatic advances in antibiotic, vaccine, and corticosteroids in the 1950’s put a halt to the growing interest in UBI therapy. Amid the enthusiasm over the new wonder drugs, only a handful of physicians continued to use it. Even though it was illogical to set aside a therapy that could treat viral diseases ( e.g., chronic hepatitis and viral pneumonia ) that were impervious to antibiotics, this illogicality came to pass. From 1955 until the 1990’s only a few American Physicians continue to work with UBI devices. It did, however receive FDA Approval status as a device that was sold and distributed in interstate commerce prior to 1976.

In Germany practitioners persisted in using Biophotonic Therapy. By the 1980’s, BT had become popular among East Germany and Russian physicians. In the 1990’s, Russian physicians began to use low-intensity lasers to treat the blood through a fiber inserted into a vein with an IV needle ( LUBI ). Now, concerns over the side effects of drugs, efforts to control costs and the HIV epidemic have led medical researchers and physicians to seek to combat infections and autoimmune diseases with innovative approaches such as BT.

Dr. Carl Schliecher; Director of the Foundation for Blood Irradiation received Exclusive Rights to the Knott Hemo-Irradiator for Canada on February 21, 1997 and for the US on July 20, 1999.

The Exclusive Rights to the Knott Hemo-Irradiator was sold to the Foundation for Blood irradiation who later sold those rights to NPC who recently assigned those Exclusive Rights to UBI Technologies. The Documents have been entered into public record in the US.

Many others in Europe and America followed the steps of Finsen and Knott, such as Miley, Christenson, Beck, Olney, Anderson, Hancock, Rebbeck, Barrett, Moser, Bland, Von Pohle, Woolfan, Hughes, Beroza, Davidson, Stauffer, Havens, Sborov, Barmasov and Collbert to mention some notable physicians. These physicians combined, performed over 300,000 clinical tests, and besides their great curative success, the most notable fact they mention is that not one person died from this treatment modality throughout 50 years of testing.

Dr. William Campbell Douglass, the Author of “Into The Light” is considered the modern day “Guru” who has had notable gains in recent years, because his treatment modality was virtually drug free and comparatively inexpensive.

Dr. Edelson at Yale University developed a form of Blood Irradiation termed “Photopheresis”, which entailed triggering chemotherapy with a small dose of UVBI.

He is also associated with Therakos®, a subsidiary of Johnson & Johnson, that has a FDA approved Photopheresis machine. The major drawback of the Therakos® treatment modality is its prohibitive cost ($5000 per treatment) and long sessions that last between four to five hours each treating only 1 disease T-Cell Lymphoma.

The Knott Hemo-Irradiator

Utilized extensively in the U.S. throughout the last 20 years.

Dr. Kent Gray received his Bachelors and Masters degrees from Central Michigan University, and his PhD in Public Health Administration from Indiana University.

Dr. Gray was deemed to be the “most innovative public health director in the State of Michigan” for his work and leadership in the control of communicable diseases and in the promotion of community-based environmental health programs.

During an epidemic of the Swartz Strain of Measles Dr. Gray discovered a vaccine that immediately saved the lives of more than 3,000 children and went on to vaccinate an additional 7,000 children.

Through this experience Dr. Gray developed a process that is now used all over the world to treat communicable diseases.

Later in his career, Dr. Gray formed a company called National Photoluminescence Center NPC which developed and build Hemo-Aide. NPC was also able to obtain the Exclusive Rights to the Patent and Trademark for the Knott Hemo-Irradiator on January 20, 2005.

Douglas Sielaff, Founder and CEO of UBI Technologies, now has Exclusive Rights to all Patents and Trademarks for the Hemo-Aide, the Q-vet, and the Knott Hemo-Irradiator.

The Lineal descent of the Knott Hemo-Irradiator, The Hemo-Aide TM

 

 

UBIMEDICAL

DISCLAIMER: THE INFORMATION PROVIDED HEREIN IS NOT INTENDED AS A “PRESCRIPTION” FOR TREATMENT, NOR IS IT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE. UBI TECHNOLOGIES AND ITS AFFILIATES MAKE NO REPRESENTATION CONCERNING THE EFFICACY, APPROPRIATENESS, OR SUITABILITY OF ANY PRODUCTS OR TREATMENTS. THE INFORMATION CONTAINED HEREIN IS FOR EDUCATIONAL PURPOSES ONLY AND THE STATEMENTS HAVE NOT BEEN EVALUATED BY THE US FOOD AND DRUG ADMINISTRATION. THE ENTIRE RISK AS TO THE USE OF THIS INFORMATION IS ASSUMED BY USER.

 

 

 
 

Copyright © 2010-2011  UBI TECHNOLOGIES - UBIMEDICAL.COM   All Rights Reserved.